Abstract：
Systemic capillary leak syndrome (SCLS) is a rare and life-threatening disorder characterised by leaking of intravascular fluid to extravascular tissues. An association with immunotherapy and COVID-19 vaccination has been reported as potential triggers. A case of a patient in her 70s developing SCLS after the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination with a history of metastatic melanoma treated with nivolumab (PD-1 monoclonal antibody) and ipilimumab (anti-CTLA4 monoclonal antibody) is reported. The aetiology and management of SCLS are also reviewed in this case context.
摘要：
系统性毛细血管渗漏综合征（SCLS）是一种罕见且危及生命的疾病，其特征是血管内液体泄漏到血管外组织。据报道，与免疫疗法和COVID-19疫苗接种相关的潜在触发因素。据报道，一名70多岁的患者在BNT162b2（Pfizer-BioNTech）COVID-19疫苗接种后发展为SCLS，有转移性黑色素瘤病史，接受了纳武单抗（PD-1单克隆抗体）和ipilimumab（抗CTLA4单克隆抗体）治疗。在这种情况下，还回顾了SCLS的病因和管理。
